| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000045 | Autophagosome assembly | Increases phenotype | PMID:30597782 |
| GO:0000080 | Mitotic g1 phase | Increases phenotype | PMID:30905860 |
| GO:0000084 | Mitotic s phase | Decreases phenotype | PMID:30905860 |
| GO:0001542 | Ovulation from ovarian follicle | Increases phenotype | PMID:19368227 |
| GO:0001890 | Placenta development | Affects phenotype | PMID:30597782 |
| GO:0002381 | Immunoglobulin production involved in immunoglobulin-mediated immune response | Increases phenotype | PMID:24051191 |
| GO:0005243 | Gap junction channel activity | Decreases phenotype | PMID:26023933 |
| GO:0006304 | Dna modification | Increases phenotype | PMID:27207664; PMID:30874336 |
| GO:0006497 | Protein lipidation | Increases phenotype | PMID:30597782 |
| GO:0006750 | Glutathione biosynthetic process | Increases phenotype | PMID:30905860 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:30905860 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:26739637 |
| GO:0006997 | Nucleus organization | Affects phenotype | PMID:30874336 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:30905860 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:27207664 |
| GO:0030521 | Androgen receptor signaling pathway | Increases phenotype | PMID:19368227 |
| GO:0032125 | Micronucleus organization | Increases phenotype | PMID:33057863 |
| GO:0032715 | Negative regulation of interleukin-6 production | Increases phenotype | PMID:31542660 |
| GO:0032755 | Positive regulation of interleukin-6 production | Increases phenotype | PMID:31542660 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:19368227 |
| GO:0042403 | Thyroid hormone metabolic process | Affects phenotype | PMID:19750101 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:30590774 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:33057863; PMID:35476398 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Affects phenotype | PMID:30905860 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:30590774; PMID:30905860 |
| GO:0070365 | Hepatocyte differentiation | Increases phenotype | PMID:26739637 |
| GO:0098705 | Copper ion import across plasma membrane | Increases phenotype | PMID:30590774 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:30905860 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Affects phenotype | PMID:30590774 |
| GO:2001269 | Positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | Increases phenotype | PMID:30590774 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.